Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ADN018
MIFTS: 59

Adenoma

Categories: Cancer diseases, Endocrine diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Adenoma

About this section

MalaCards integrated aliases for Adenoma:

Name: Adenoma 12 74 54 15 71
Acinar Cell Adenoma 12 71
Adenomas 12 15
Acinic Cell Adenoma 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:657
MeSH 44 D000236
NCIt 50 C2855 C4196
SNOMED-CT 67 443416007 79041005
UMLS 71 C0001430 C0334389
Sources

Summaries for Adenoma

About this section
Disease Ontology : 12 A cell type benign neoplasm that is composed of epithelial tissue in which tumor cells form glands or glandlike structures.

MalaCards based summary : Adenoma, also known as acinar cell adenoma, is related to acth-secreting pituitary adenoma and pituitary adenoma, prolactin-secreting. An important gene associated with Adenoma is PLAG1 (PLAG1 Zinc Finger), and among its related pathways/superpathways are Signaling by GPCR and Toll-like Receptor Signaling Pathway. The drugs Clopidogrel and Scopolamine have been mentioned in the context of this disorder. Affiliated tissues include pituitary, thyroid and colon, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 74 An adenoma is a benign tumor of epithelial tissue with glandular origin, glandular characteristics, or... more...

Sources

Related Diseases for Adenoma

About this section

Diseases related to Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1790)
# Related Disease Score Top Affiliating Genes
1 acth-secreting pituitary adenoma 33.2 MEN1 GNAS AIP
2 pituitary adenoma, prolactin-secreting 33.1 MEN1 GNAS AIP
3 colorectal adenoma 33.0 MSH2 MLH1 KRAS CTNNB1 CCND1 APC
4 parathyroid adenoma 33.0 RET MEN1 GNAS CTNNB1 CDC73 CCND1
5 familial isolated pituitary adenoma 33.0 MEN1 AIP
6 pleomorphic adenoma 32.9 PLAGL2 PLAG1 CTNNB1
7 villous adenoma 32.9 MLH1 KRAS GNAS BRAF APC
8 growth hormone secreting pituitary adenoma 32.8 MEN1 GNAS AIP
9 follicular adenoma 32.7 TSHR RET MEN1 GNAS BRAF
10 sebaceous adenoma 32.7 MSH6 MSH2 MLH1
11 clear cell adenoma 32.6 MEN1 CDC73
12 apocrine adenoma 32.5 KRAS BRAF
13 colon adenoma 32.4 SMAD4 KRAS CTNNB1 APC
14 hyperparathyroidism 2 with jaw tumors 32.4 RET MEN1 CDC73 CCND1
15 primary hyperparathyroidism 32.4 RET MEN1 GNAS CDC73 CCND1 AIP
16 extrahepatic bile duct adenoma 32.3 MSH6 MSH2 MLH1
17 carney complex variant 32.3 RET MEN1 GNAS CTNNB1 AIP
18 multiple endocrine neoplasia 32.3 RET MEN1 GNAS CDC73 AIP
19 periampullary adenoma 32.2 MSH6 KRAS APC
20 hyperpituitarism 32.2 MEN1 GNAS AIP
21 precocious puberty, male-limited 32.2 TSHR LHCGR GNAS
22 mismatch repair cancer syndrome 1 32.1 MSH6 MSH2 MLH1 CTNNB1 APC
23 pituitary tumors 32.1 MEN1 GNAS AIP
24 primary pigmented nodular adrenocortical disease 32.0 MEN1 GNAS CTNNB1
25 null pituitary adenoma 32.0 MEN1 AIP
26 parathyroid carcinoma 32.0 RET MEN1 CTNNB1 CDC73 CCND1 APC
27 endometrial adenocarcinoma 32.0 MLH1 KRAS CTNNB1 CCND1
28 familial adenomatous polyposis 31.9 SMAD4 MSH6 MSH2 MLH1 KRAS CTNNB1
29 silent pituitary adenoma 31.9 MSH6 MSH2 MEN1 AIP
30 thyroid carcinoma 31.8 TSHR RET BRAF
31 juvenile polyposis syndrome 31.7 SMAD4 MSH6 MSH2 MLH1 CTNNB1 APC
32 goiter 31.6 TSHR RET GNAS
33 hyperparathyroidism 1 31.5 MEN1 CDC73
34 adenoid cystic carcinoma 31.5 PLAG1 KRAS CTNNB1 CCND1
35 adenocarcinoma 31.3 SMAD4 RET MSH6 MSH2 MLH1 KRAS
36 multiple endocrine neoplasia, type i 31.2 RET MEN1 GNAS CDC73 AIP
37 craniopharyngioma 31.2 CTNNB1 BRAF APC
38 hemangioma 31.1 RET MEN1 KRAS CTNNB1
39 peutz-jeghers syndrome 31.1 SMAD4 GNAS CTNNB1 APC
40 appendix adenocarcinoma 31.1 KRAS GNAS
41 gastric adenocarcinoma 31.1 SMAD4 MLH1 KRAS GNAS CTNNB1 BRAF
42 ovarian serous cystadenocarcinoma 31.1 KRAS GNAS BRAF
43 thyroid gland follicular carcinoma 31.0 TSHR RET KRAS CTNNB1 CCND1 BRAF
44 thyroid tumor 31.0 RET BRAF
45 thyroid carcinoma, familial medullary 31.0 RET MEN1 KRAS BRAF
46 nodular goiter 31.0 TSHR RET BRAF
47 signet ring cell adenocarcinoma 31.0 MSH2 MLH1 KRAS CTNNB1
48 cholangiocarcinoma 31.0 SMAD4 KRAS CTNNB1 BRAF APC
49 intrahepatic cholangiocarcinoma 30.9 SMAD4 KRAS CTNNB1 CCND1 APC
50 mccune-albright syndrome 30.9 MEN1 GNAS APC

Graphical network of the top 20 diseases related to Adenoma:



Diseases related to Adenoma
Sources

Symptoms & Phenotypes for Adenoma

About this section

GenomeRNAi Phenotypes related to Adenoma according to GeneCards Suite gene sharing:

26 (show top 50) (show all 56)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-1 10.52 MLH1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.52 SMAD4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.52 SMAD4
4 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.52 PLAGL2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-111 10.52 MEN1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.52 KRAS
7 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.52 MLH1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.52 PLAGL2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-128 10.52 MEN1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.52 RET
11 Increased shRNA abundance (Z-score > 2) GR00366-A-133 10.52 APC
12 Increased shRNA abundance (Z-score > 2) GR00366-A-134 10.52 CCND1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-141 10.52 PLAGL2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.52 BRAF
15 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.52 CCND1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-153 10.52 MEN1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.52 RET
18 Increased shRNA abundance (Z-score > 2) GR00366-A-18 10.52 PLAG1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-192 10.52 APC
20 Increased shRNA abundance (Z-score > 2) GR00366-A-195 10.52 MLH1 SMAD4
21 Increased shRNA abundance (Z-score > 2) GR00366-A-200 10.52 MLH1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.52 APC
23 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.52 PLAG1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.52 CCND1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.52 CCND1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-211 10.52 CCND1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-212 10.52 SMAD4
28 Increased shRNA abundance (Z-score > 2) GR00366-A-213 10.52 RET
29 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.52 KRAS
30 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.52 SMAD4
31 Increased shRNA abundance (Z-score > 2) GR00366-A-28 10.52 RET
32 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.52 CCND1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.52 SMAD4
34 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.52 CTNNB1 MEN1 BRAF
35 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.52 PLAG1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.52 RET
37 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.52 RET
38 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.52 KRAS
39 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.52 RET
40 Increased shRNA abundance (Z-score > 2) GR00366-A-78 10.52 MLH1
41 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.52 PLAGL2
42 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.52 RET
43 Increased shRNA abundance (Z-score > 2) GR00366-A-98 10.52 MEN1
44 Decreased viability GR00055-A-1 10.26 BRAF KRAS
45 Decreased viability GR00055-A-2 10.26 BRAF KRAS
46 Decreased viability GR00055-A-3 10.26 KRAS
47 Decreased viability GR00106-A-0 10.26 KRAS
48 Decreased viability GR00221-A-1 10.26 KRAS RET
49 Decreased viability GR00221-A-2 10.26 KRAS RET
50 Decreased viability GR00221-A-4 10.26 BRAF RET

MGI Mouse Phenotypes related to Adenoma:

46 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.52 AIP APC BRAF CCND1 CDC73 CTNNB1
2 homeostasis/metabolism MP:0005376 10.5 AIP APC BRAF CCND1 CDC73 CTNNB1
3 endocrine/exocrine gland MP:0005379 10.46 AIP APC BRAF CCND1 CDC73 CTNNB1
4 growth/size/body region MP:0005378 10.45 AIP APC BRAF CCND1 CDC73 CTNNB1
5 hematopoietic system MP:0005397 10.44 APC BRAF CCND1 CDC73 CTNNB1 GNAS
6 behavior/neurological MP:0005386 10.42 APC BRAF CCND1 CDC73 CTNNB1 GNAS
7 digestive/alimentary MP:0005381 10.42 APC BRAF CCND1 CDC73 CTNNB1 KRAS
8 immune system MP:0005387 10.41 APC BRAF CCND1 CDC73 CTNNB1 GNAS
9 cardiovascular system MP:0005385 10.38 AIP APC BRAF CCND1 CDC73 CTNNB1
10 mortality/aging MP:0010768 10.36 AIP APC BRAF CCND1 CDC73 CTNNB1
11 craniofacial MP:0005382 10.28 APC BRAF CCND1 CDC73 CTNNB1 GNAS
12 embryo MP:0005380 10.27 AIP APC BRAF CDC73 CTNNB1 KRAS
13 integument MP:0010771 10.27 AIP APC BRAF CCND1 CDC73 CTNNB1
14 neoplasm MP:0002006 10.24 AIP APC BRAF CCND1 CDC73 CTNNB1
15 liver/biliary system MP:0005370 10.16 AIP APC BRAF CDC73 CTNNB1 GNAS
16 limbs/digits/tail MP:0005371 10.13 APC BRAF CTNNB1 GNAS KRAS PLAG1
17 nervous system MP:0003631 10.13 APC BRAF CCND1 CDC73 CTNNB1 GNAS
18 muscle MP:0005369 10.06 APC BRAF CDC73 CTNNB1 GNAS KRAS
19 reproductive system MP:0005389 9.97 APC BRAF CCND1 CDC73 CTNNB1 KRAS
20 renal/urinary system MP:0005367 9.91 APC BRAF CDC73 CTNNB1 GNAS KRAS
21 respiratory system MP:0005388 9.61 BRAF CCND1 CDC73 CTNNB1 GNAS KRAS
22 skeleton MP:0005390 9.32 APC BRAF CCND1 CDC73 CTNNB1 GNAS
Sources

Drugs & Therapeutics for Adenoma

About this section

Drugs for Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 374)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
2
Scopolamine Approved, Investigational Phase 4 51-34-3, 6533-68-2 5184
3
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
4
Sulfamethoxazole Approved Phase 4 723-46-6 5329
5
Cefdinir Approved Phase 4 91832-40-5 6915944
6
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
7
Cefazolin Approved Phase 4 25953-19-9 656510 33255
8
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
9
Dyclonine Approved Phase 4 586-60-7 3180
10
Metformin Approved Phase 4 657-24-9 14219 4091
11
Simethicone Approved Phase 4 8050-81-5
12
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
13
Sodium sulfate Approved, Vet_approved Phase 4 7757-82-6
14
Liraglutide Approved Phase 4 204656-20-2 44147092
15
Quinagolide Approved, Investigational Phase 4 87056-78-8, 97805-50-0 105105
16
Somatostatin Approved, Investigational Phase 4 51110-01-1, 38916-34-6 53481605
17
Lactitol Approved, Investigational Phase 4 585-86-4 157355
18
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
19
Cabergoline Approved Phase 4 81409-90-7 54746
20
Pasireotide Approved Phase 4 396091-73-9 9941444
21
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
22
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
23
Acetaminophen Approved Phase 4 103-90-2 1983
24
Codeine Approved, Illicit Phase 4 76-57-3 5284371
25
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
26
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
27
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
28 Anesthetics Phase 4
29 Purinergic P2Y Receptor Antagonists Phase 4
30 Anesthetics, Local Phase 4
31 Antiparasitic Agents Phase 4
32 Antiprotozoal Agents Phase 4
33 Anticonvulsants Phase 4
34 Parasympatholytics Phase 4
35 Cholinergic Antagonists Phase 4
36 Muscarinic Antagonists Phase 4
37 Butylscopolammonium Bromide Phase 4
38 Cholinergic Agents Phase 4
39 Bromides Phase 4
40 Cytochrome P-450 Enzyme Inhibitors Phase 4
41 Folic Acid Antagonists Phase 4
42 cefuroxime axetil Phase 4
43 Clindamycin palmitate Phase 4
44 Clindamycin phosphate Phase 4
45 Cephalosporins Phase 4
46 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
47 Antimalarials Phase 4
48 Proton Pump Inhibitors Phase 4
49 Cathartics Phase 4
50 Laxatives Phase 4

Interventional clinical trials:

(show top 50) (show all 682)
# Name Status NCT ID Phase Drugs
1 Efficacy and Cost-effectiveness of Colonoscopy vs. Combined Fecal Immunochemical Test-Sigmoidoscopy for the Detection of Advanced Colorectal Neoplasia (eCOLO-FITS): A Randomized Multicenter Trial Unknown status NCT01767870 Phase 4
2 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
3 Does Hyoscine N-butylbromide Administered During Colonoscopy Increase the Polyp Detection Rate? a Randomized, Single Center, Double Blind, Placebo-controlled Study Unknown status NCT01609855 Phase 4 Hyoscine Butyl Bromide 20mg/2 ml i.v.;Saline 2 ml i.v.
4 Prophylactic Pancreatic Duct Stent Placement After Endoscopic Snare Papillectomy of Duodenal Major Papillary Tumors; Prospective, Randomized, Controlled Study Unknown status NCT01737463 Phase 4
5 Impact of Reinforced Education by Wechat and Short Message Service on the Quality of Bowel Preparation Unknown status NCT02832869 Phase 4
6 A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Evaluating the Impact of Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Unknown status NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
7 Premedication Dyclonine Improves Visibility During Bowel Cleansing for Colonoscopy Unknown status NCT03352700 Phase 4 3L PEG;3L PEG+Dyclonine Hydrochloride Mucilage
8 Comparison of the Efficacy and Tolerability Between 3-L and 4-L Polyethylene Glycol in Bowel Preparation Unknown status NCT03356015 Phase 4 4L Polyethylene Glycol;3L Polyethylene Glycol
9 Clinical Effectiveness of Serum Chromogranin A (CgA) Levels on Diagnostic Relevance, Response After Surgical Resection and Recurrence of Pancreatic Endocrine Tumors (PET) Unknown status NCT02759718 Phase 4
10 Can Involvement of Endoscopy Nurse Participation Increase Adenoma Detection Rate During Screening Colonoscopy?:A Prospective Multicenter Randomized Trial Completed NCT01124266 Phase 4
11 A SINGLE-ARM OPEN-LABEL INTERNATIONAL MULTI-CENTER STUDY OF THE EFFICACY AND SAFETY OF SUNITINIB MALATE (SU011248, SUTENT (REGISTERED)) IN PATIENTS WITH PROGRESSIVE ADVANCED METASTATIC WELL-DIFFERENTIATED UNRESECTABLE PANCREATIC NEUROENDOCRINE TUMORS Completed NCT01525550 Phase 4 sunitinib
12 Evaluation of the Effects of Monopolar Transurethral Resection Versus Bipolar Transurethral Resection and Holmium Laser Enucleation of the Prostate on Urinary and Sexual Function; a Prospective Comparative Study. Completed NCT01810068 Phase 4
13 Randomized Study Comparing Holmium Laser Enucleation of the Prostate (HOLEP) Versus Greenlight (XPS) Laser Photoselective Vapo-Enucleation of Prostate(PVEP) in the Management of Infravesical Obstruction Secondary to BPH Completed NCT01494337 Phase 4
14 Green Light Laser (XPS) Photoselective Vaporization of the Prostate (PVP) Versus Bipolar Transurethral Vaporization (B.TUVP) of the Prostate for Treatment of Small to Moderate Sized Benign Prostate Hyperplasia: A Randomized Study Completed NCT02283684 Phase 4
15 Prospective, Multicenter Study for the Evaluation of Safety and Performance of the Interscope EndoRotor Endoscopic Mucosal Resection System for the Removal of Alimentary Tract Mucosa in the Colon Completed NCT04203667 Phase 4
16 Comparative Efficacy of Water & Indigo Carmine vs Water or Air Method Completed NCT01607255 Phase 4 Indigo carmine
17 Does Surgical Debulking Of Pituitary Adenomas Improve Responsiveness To Octreotide LAR In The Treatment Of Acromegaly: An Investigator-Initiated Study Completed NCT01371643 Phase 4 Octreotide LAR
18 Preoperative Octreotide Treatment of Patients With Growth Hormone Producing Pituitary Adenomas Completed NCT00521300 Phase 4 Octreotide
19 The Effect Of Adding High Dose Simethicone To A Standard Polyethylene Glycol Preparation On Adenoma Detection Rate During Screening Colonoscopy: A Randomized Controlled Pilot Trial Completed NCT03119168 Phase 4 Simethicone Solution
20 Effects of Ilaprazole 20mg on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone Endoscopic Submucosal Dissection(ESD) for Gastric Adenoma or Early Gastric Cancer. Completed NCT02638584 Phase 4 Ilaprazole;Rabeprazole
21 Effect of Gum Chewing on Bowel Cleansing Before Colonoscopy: A Prospective Randomized Study Completed NCT02507037 Phase 4 polyethylene glycol
22 A Multicentre Randomized Parallel Group Phase IV Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of PLENVU® Versus SELG-ESSE® Using a 2-Day Split Dosing Regimen. Completed NCT03742232 Phase 4 PEG3350;Macrogol 4000
23 A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
24 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment: Correlation With Disease Activity, Insulin Sensitivity and Secretion Parameters Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
25 PRolaCT - Three Multicenter Prolactinoma Randomized Clinical Trials Recruiting NCT04107480 Phase 4 Dopamine Agonists
26 Minimizing Narcotic Analgesics After Thyroid or Parathyroid Surgery Active, not recruiting NCT03469310 Phase 4 Acetaminophen 500Mg Cap;Tylenol #3 Oral Tablet;Tramadol
27 An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment Active, not recruiting NCT01794793 Phase 4 Pasireotide;Cabergoline;Pasireotide
28 Phase IV, Open-label, Multi-center, Single-arm Study of the Safety and Efficacy of Everolimus (Afinitor) in Adult Patients With Local Advanced or Metastatic, Well Differentiated Progressive Pancreatic Neuroendocrine Tumors (pNET) in China. Active, not recruiting NCT02842749 Phase 4 everolimus
29 Transanal Endoscopic Microsurgery Versus Endoscopic Submucosal Dissection For Large Rectal Adenomas Suspended NCT01023984 Phase 4
30 Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding Terminated NCT02032784 Phase 4 octreotide
31 Calcium Plus Vitamin D Supplementation in Prevention of Colorectal Adenomas Recurrence:a Prospective, Randomized, Placebo-controlled, Multicenter Clinical Trial Unknown status NCT02143505 Phase 2, Phase 3 Ca plus vit D
32 Efficiency of Ursodesoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis Patients. URSOPAF Unknown status NCT00134758 Phase 2, Phase 3 Ursodeoxycholic acid;Placebo
33 GRAND BLEU Study: Does the Colonoscopy With Instillation of Blue Water (Indigo Carmin® Dilute) Enable an Improved Rate of Adenoma Detection for Colonoscopy With Insufflation of Air? Unknown status NCT01937429 Phase 3
34 Efficacy of Bispectral Index Monitoring for Midazolam and Meperidine Induced Sedation During Endoscopic Submucosal Dissection Unknown status NCT01157598 Phase 3
35 A Prospective Comparative Study of Papillectomy Completed NCT02165852 Phase 3
36 Towards Cost-effective Management of Patients With Hypertension Due to Primary Aldosteronism: Adrenal Vein Sampling or Ct-scan? Completed NCT01096654 Phase 3
37 Somatostatin and Dopamine Receptors Expression in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vitro and in Vivo Responsiveness to Somatostatin Analogs and Dopamine Agonist Completed NCT01620138 Phase 2, Phase 3 Pasireotide;cabergoline
38 A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study With In-House Blinding to Determine the Effect of 156 Weeks of Treatment With MK0966 on the Recurrence of Neoplastic Polyps of the Large Bowel in Patients With a History of Colorectal Adenomas Completed NCT00282386 Phase 3 MK0966; Rofecoxib / Duration of Treatment: 156 weeks;Placebo/ Duration of Treatment: 156 weeks
39 A Randomized, Placebo-controlled, Multicenter, Prospective Clinical Study of Berberine Hydrochloride in Preventing Recurrence and Carcinogenesis After Endoscopic Removal of Colorectal Adenomas Completed NCT02226185 Phase 2, Phase 3 Berberine hydrochloride;placebo
40 CSP #380 - Prospective Evaluation of Risk Factors for Large (> 1 CM) Colonic Adenomas in Asymptomatic Subjects Completed NCT00032344 Phase 3
41 Prevention of Sporadic Colorectal Adenomas With Celecoxib Completed NCT00005094 Phase 3 celecoxib
42 Prevention of Progression of Duodenal Adenomas to Cancer in Patients With Familial Adenomatous Polyposis (FAP) Completed NCT00808743 Phase 2, Phase 3 Celecoxib;Ursodeoxycholic acid;Placebo
43 Dopamine Agonist Cabergoline in Residual Clinically Nonfunctioning Pituitary Adenoma After Transphenoidal Surgery: A Single Center, Open Label and Randomized Clinical Trial Completed NCT03271918 Phase 3 Cabergoline
44 Colorectal Adenoma Chemoprevention Trial Using Aspirin: A Phase III Study Completed NCT00002527 Phase 3 aspirin
45 Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP) Completed NCT00141193 Phase 3 Celecoxib
46 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3 Cabergoline
47 Aspirin/Folate Prevention of Large Bowel Polyps Completed NCT00272324 Phase 2, Phase 3 Aspirin;Folate
48 Vitamin D/Calcium Polyp Prevention Study Completed NCT00153816 Phase 2, Phase 3 Calcium Carbonate;Vitamin D3;placebo
49 Colonoscopy Screening Using a Novel Slim Colonoscope - a Randomized Controlled Trial Completed NCT01370928 Phase 3
50 Phase III Open-labeled Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy Completed NCT01411189 Phase 3 Menthol

Search NIH Clinical Center for Adenoma

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Octreotide
Octreotide Acetate
Sources

Genetic Tests for Adenoma

About this section
Sources

Anatomical Context for Adenoma

About this section

MalaCards organs/tissues related to Adenoma:

40
Pituitary, Thyroid, Colon, Salivary Gland, Prostate, Pancreas, Liver
Sources

Publications for Adenoma

About this section

Articles related to Adenoma:

(show top 50) (show all 52458)
# Title Authors PMID Year
1
Differentiation of tubular and villous adenomas based on Wnt pathway-related gene expression profiles. 61 54
20514431 2010
2
Biallelic MYH germline mutations as cause of Muir-Torre syndrome. 61 54
19998059 2010
3
Wnt signaling may be activated in a subset of Peutz-Jeghers syndrome polyps closely correlating to LKB1 expression. 54 61
20428811 2010
4
The safety and efficacy of celecoxib in children with familial adenomatous polyposis. 54 61
20234350 2010
5
Adrenocortical zonation in humans under normal and pathological conditions. 54 61
20200334 2010
6
Nuclear or cytoplasmic localization of Bag-1 distinctly correlates with pathologic behavior and outcome of gastric carcinomas. 61 54
20096920 2010
7
Immunohistochemical detection of somatostatin receptor subtype 5 (SSTR-5) in cushing adenoma. 61 54
19894022 2010
8
Expression of Lgr5 in human colorectal carcinogenesis and its potential correlation with beta-catenin. 54 61
20195621 2010
9
ACB-PCR quantification of K-RAS codon 12 GAT and GTT mutant fraction in colon tumor and non-tumor tissue. 54 61
20307197 2010
10
Oncogenic KRAS is not necessary for Wnt signalling activation in APC-associated FAP adenomas. 61 54
20196079 2010
11
Fish fatty acids alter markers of apoptosis in colorectal adenoma and adenocarcinoma cell lines but fish consumption has no impact on apoptosis-induction ex vivo. 61 54
20107900 2010
12
AMACR is associated with advanced pathologic risk factors in sporadic colorectal adenomas. 54 61
20503447 2010
13
Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention. 54 61
20427397 2010
14
KRAS mutations in traditional serrated adenomas from Korea herald an aggressive phenotype. 54 61
20305537 2010
15
The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. 61 54
20335450 2010
16
Clear cell adenocarcinoma of the bladder and urethra: cases diffusely mimicking nephrogenic adenoma. 54 61
20060152 2010
17
REG IV overexpression in an early stage of colorectal carcinogenesis: an immunohistochemical study. 54 61
20183800 2010
18
Chemoprophylaxis in gastrointestinal tumors. 54 61
20496537 2010
19
Effects of calcium and vitamin D on MLH1 and MSH2 expression in rectal mucosa of sporadic colorectal adenoma patients. 61 54
20332274 2010
20
High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. 54 61
20145615 2010
21
Complete deletion of Apc results in severe polyposis in mice. 54 61
20010873 2010
22
Increased expression of HMGA1 correlates with tumour invasiveness and proliferation in human pituitary adenomas. 61 54
20459557 2010
23
Pituitary adenomas that show a faint GH-immunoreactivity but lack fibrous body: Pit-1 adenoma with endocrinologically low activity. 61 54
20111911 2010
24
Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study. 61 54
20233436 2010
25
Beta-catenin activation is not involved in sporadic parathyroid carcinomas and adenomas. 54 61
19755524 2010
26
Frequent promoter hypermethylation of the APC and RASSF1A tumour suppressors in parathyroid tumours. 61 54
20208994 2010
27
Identification of histologically distinct conventional adenomas that arise predominately in patients with sessile serrated adenomas. 61 54
20118768 2010
28
Immunohistochemical expression of pituitary tumor transforming gene (PTTG) in pituitary adenomas: a correlative study of tumor subtypes. 54 61
20106827 2010
29
Genetic polymorphisms in vitamin D receptor VDR/RXRA influence the likelihood of colon adenoma recurrence. 61 54
20145122 2010
30
The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. 61 54
20093774 2010
31
Genetic variation in prostaglandin E2 synthesis and signaling, prostaglandin dehydrogenase, and the risk of colorectal adenoma. 61 54
20086108 2010
32
Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor. 54 61
20087348 2010
33
O-methylguanine-DNA methyltransferase immunoexpression in a double pituitary adenoma: case report. 54 61
20087113 2010
34
Expression of gastric pyloric mucin, MUC6, in colorectal serrated polyps. 54 61
19855374 2010
35
Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. 61 54
19965918 2010
36
[Differentiated therapy of liver tumors]. 54 61
20062959 2010
37
Elevation of growth hormone secretagogue receptor type 1a mRNA expression in human growth hormone-secreting pituitary adenoma harboring G protein alpha subunit mutation. 61 54
20150876 2010
38
ACTH-independent Cushing's syndrome with bilateral micronodular adrenal hyperplasia and ectopic adrenocortical adenoma. 61 54
19915020 2010
39
HERG1 gene expression as a specific tumor marker in colorectal tissues. 61 54
19577877 2010
40
Identifying mutations for MYH-associated polyposis. 54 61
20063264 2010
41
Gradual loss of functional gap junction within progression of colorectal cancer -- a shift from membranous CX32 and CX43 expression to cytoplasmic pattern during colorectal carcinogenesis. 61 54
20133984 2010
42
Immunohistochemistry of COUP-TFI: an adjuvant diagnostic tool for the identification of corticotroph microadenomas. 54 61
19526345 2010
43
CT-MIBI-SPECT image fusion predicts multiglandular disease in hyperparathyroidism. 54 61
19705144 2010
44
Molecular genetics of hepatocellular neoplasia. 61 54
20182587 2010
45
Differential effects of reactive nitrogen species on DNA base excision repair initiated by the alkyladenine DNA glycosylase. 54 61
19864471 2009
46
A case of Peutz-Jeghers syndrome with breast cancer, bilateral sex cord tumor with annular tubules, and adenoma malignum caused by STK11 gene mutation. 54 61
19955943 2009
47
Clear cell change in colonic polyps. 54 61
18611940 2009
48
Cyclooxygenase-2 expression is related to the epithelial-to-mesenchymal transition in human colon cancers. 54 61
20046424 2009
49
Beta-catenin nuclear labeling is a common feature of sessile serrated adenomas and correlates with early neoplastic progression after BRAF activation. 61 54
19745699 2009
50
Synaptophysin immunoreactivity in adrenocortical adenomas: a correlation between synaptophysin and CYP17A1 expression. 61 54
19755404 2009
Sources

Variations for Adenoma

About this section
Sources

Expression for Adenoma

About this section
Search GEO for disease gene expression data for Adenoma.
Sources

Pathways for Adenoma

About this section

Pathways related to Adenoma according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 65
Show member pathways
 14.15 TSHR SMAD4 RET MEN1 LHCGR KRAS
2
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 12.99 SMAD4 KRAS GNAS CTNNB1 CCND1 BRAF
3
Aldosterone synthesis and secretion 36
Show member pathways
 12.74 TSHR MEN1 KRAS GNAS CTNNB1 CCND1
4
Gastric cancer 36
Show member pathways
 12.67 SMAD4 MLH1 KRAS CTNNB1 CCND1 BRAF
5
Endometrial cancer 36
Show member pathways
 12.6 SMAD4 RET MSH6 MSH2 MLH1 KRAS
6
Glioma 36
Show member pathways
 12.56 RET MSH6 KRAS GNAS CCND1 BRAF
7
Human Embryonic Stem Cell Pluripotency 63
Show member pathways
 12.43 SMAD4 GNAS CTNNB1 APC
8
Mesodermal Commitment Pathway 1
Show member pathways
 12.42 SMAD4 CTNNB1 CDC73 CCND1 APC
9
Pathways in cancer 36
12.42 SMAD4 RET MSH6 MSH2 MLH1 KRAS
10
WNT Signaling 63
12.39 GNAS CTNNB1 CCND1 APC
11
DNA Damage 4
12.39 MSH6 MSH2 MLH1 CDC73 CCND1
12
Cell cycle 36 1
12.31 SMAD4 MEN1 CCND1 APC
13
cAMP signaling pathway 36
12.27 TSHR LHCGR GNAS BRAF
14
Proteoglycans in cancer 36
12.24 KRAS CTNNB1 CCND1 BRAF
15
Wnt / Hedgehog / Notch 4
12.17 SMAD4 CTNNB1 CDC73 APC
16
Wnt signaling pathway 36
12.1 SMAD4 CTNNB1 CCND1 APC
17
Hippo signaling pathway 36
12.07 SMAD4 CTNNB1 CCND1 APC
18
Signaling pathways regulating pluripotency of stem cells 36
12.01 SMAD4 KRAS CTNNB1 APC
19
FoxO signaling pathway 36
Show member pathways
 11.99 SMAD4 KRAS CCND1 BRAF
20
Integrated Breast Cancer Pathway 1
11.99 SMAD4 MSH6 MSH2 KRAS CTNNB1 CCND1
21
DNA Damage Response (only ATM dependent) 1
11.89 SMAD4 KRAS CTNNB1 CCND1 APC
22
Glioblastoma Multiforme 63
11.85 KRAS CTNNB1 CCND1 BRAF APC
23
TGF-beta Signaling Pathways 64
11.84 SMAD4 KRAS BRAF
24
Mismatch repair 36 65 1
Show member pathways
 11.83 MSH6 MSH2 MLH1
25
Corticotropin-releasing hormone signaling pathway 1
11.82 GNAS CTNNB1 BRAF
26
Androgen receptor signaling pathway 1
11.8 SMAD4 CTNNB1 CCND1
27
VEGF Pathway (Tocris) 60
Show member pathways
 11.75 RET KRAS BRAF
28
Regulation of Wnt-mediated beta catenin signaling and target gene transcription 1
11.73 CTNNB1 CCND1 APC
29
Platinum drug resistance 36
11.69 MSH6 MSH2 MLH1
30
Bladder cancer 36 1
11.68 KRAS CCND1 BRAF
31
Human Thyroid Stimulating Hormone (TSH) signaling pathway 1
11.64 TSHR GNAS BRAF
32
Long-term depression 36
11.57 KRAS GNAS BRAF
33
Colorectal Cancer Metastasis 63
11.54 SMAD4 MSH6 MSH2 MLH1 KRAS GNAS
34
Wnt Signaling Pathway Netpath 1
11.51 CTNNB1 CCND1 APC
35
Aryl Hydrocarbon Receptor 1
11.46 RET KRAS AIP
36
Presenilin action in Notch and Wnt signaling 1
11.42 CTNNB1 CCND1 APC
37
Deactivation of the beta-catenin transactivating complex 65
11.38 MEN1 CTNNB1 APC
38
Platinum Pathway, Pharmacokinetics/Pharmacodynamics 60
11.15 MSH6 MSH2 MLH1
39
Extracellular vesicle-mediated signaling in recipient cells 1
11.15 SMAD4 KRAS CTNNB1 APC
40
Wnt/beta-catenin Signaling Pathway in Leukemia 1
11.05 CTNNB1 CCND1 APC
41
RHO GTPases activate IQGAPs 65
10.78 MEN1 CTNNB1
42
Hormone ligand-binding receptors 65
10.78 TSHR LHCGR
Sources

GO Terms for Adenoma

About this section

Cellular components related to Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 10 SMAD4 PLAG1 MSH6 MSH2 MLH1 MEN1
2 cytosol GO:0005829 9.97 THADA SMAD4 PLAG1 MSH6 MEN1 KRAS
3 beta-catenin destruction complex GO:0030877 9.37 CTNNB1 APC
4 Wnt signalosome GO:1990909 9.32 CTNNB1 APC
5 MutSalpha complex GO:0032301 8.96 MSH6 MSH2
6 mismatch repair complex GO:0032300 8.8 MSH6 MSH2 MLH1

Biological processes related to Adenoma according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.97 RET PLAG1 KRAS CTNNB1 BRAF
2 negative regulation of cell proliferation GO:0008285 9.95 SMAD4 MEN1 CTNNB1 CDC73 APC
3 MAPK cascade GO:0000165 9.91 RET MEN1 KRAS BRAF
4 Wnt signaling pathway GO:0016055 9.87 CTNNB1 CDC73 CCND1 APC
5 cellular response to DNA damage stimulus GO:0006974 9.85 MSH6 MSH2 MLH1 MEN1 CCND1 APC
6 positive regulation of cold-induced thermogenesis GO:0120162 9.77 TSHR GNAS APC
7 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.63 MSH6 MSH2 MLH1
8 activation of adenylate cyclase activity GO:0007190 9.61 TSHR LHCGR GNAS
9 positive regulation of transcription elongation from RNA polymerase II promoter GO:0032968 9.59 CTNNB1 CDC73
10 response to transforming growth factor beta GO:0071559 9.58 SMAD4 MEN1
11 mismatch repair GO:0006298 9.58 MSH6 MSH2 MLH1
12 positive regulation of isotype switching to IgG isotypes GO:0048304 9.56 MSH2 MLH1
13 positive regulation of helicase activity GO:0051096 9.54 MSH6 MSH2
14 endodermal cell fate commitment GO:0001711 9.52 CTNNB1 CDC73
15 hair follicle placode formation GO:0060789 9.51 GNAS CTNNB1
16 beta-catenin-TCF complex assembly GO:1904837 9.5 MEN1 CTNNB1 CDC73
17 positive regulation of isotype switching to IgA isotypes GO:0048298 9.49 MSH2 MLH1
18 maintenance of DNA repeat elements GO:0043570 9.48 MSH6 MSH2
19 isotype switching GO:0045190 9.33 MSH6 MSH2 MLH1
20 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.26 MSH2 MLH1
21 somatic hypermutation of immunoglobulin genes GO:0016446 9.13 MSH6 MSH2 MLH1
22 somatic recombination of immunoglobulin gene segments GO:0016447 8.8 MSH6 MSH2 MLH1

Molecular functions related to Adenoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.8 MSH6 MSH2 MLH1 CTNNB1 CCND1
2 chromatin binding GO:0003682 9.73 SMAD4 MSH6 MSH2 MLH1 MEN1 CTNNB1
3 I-SMAD binding GO:0070411 9.49 SMAD4 CTNNB1
4 protein-hormone receptor activity GO:0016500 9.48 TSHR LHCGR
5 MutLalpha complex binding GO:0032405 9.46 MSH6 MSH2
6 oxidized purine DNA binding GO:0032357 9.43 MSH6 MSH2
7 single guanine insertion binding GO:0032142 9.37 MSH6 MSH2
8 four-way junction DNA binding GO:0000400 9.33 MSH6 MSH2 MEN1
9 single thymine insertion binding GO:0032143 9.32 MSH6 MSH2
10 mismatched DNA binding GO:0030983 9.13 MSH6 MSH2 MLH1
11 guanine/thymine mispair binding GO:0032137 8.8 MSH6 MSH2 MLH1
Sources

Sources for Adenoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....